In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aimmune Therapeutics Inc.

www.aimmune.com

Latest From Aimmune Therapeutics Inc.

Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount

BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
Financing StartUps and SMEs

US FDA AdComm Win For Aimmune’s Palforzia Bodes Well For DBV’s Peanut Allergy Patch

Aimmune’s oral immunotherapy seems destined to come to market with a strict REMS, though analysts do not expect this will impact adoption. DBV is awaiting word on whether the FDA will review its second attempt at a BLA submission for Viaskin Peanut.

Advisory Committees Drug Review

Aimmune’s Palforzia Gains US FDA Panel Nod But Faces REMS Restrictions

The agency’s plan to require a Risk Evaluation and Mitigation Strategy aimed at systemic allergic reactions with the peanut allergy immunotherapy did not go far enough, advisory committee members said, pushing for additional measures to be folded into the program.

Advisory Committees Drug Review

Aimmune’s Peanut Allergy Immunotherapy Brings Safety Concerns To US FDA Panel

Palforzia was associated with a higher rate of adverse events, systemic allergic reactions, eosinophilic esophagitis and epinephrine use in controlled clinical trials; Allergenic Products Advisory Committee will weigh approval for patients ages 4-17 years with confirmed peanut allergy diagnosis.

Advisory Committees Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • Allergen Research Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aimmune Therapeutics Inc.
  • Senior Management
  • Jayson Dallas, Pres. & CEO
    Eric Bjerkholt, CFO
    Jeffrey H Knapp, PhD, COO
    Daniel C Adelman, MD, CMO
    Mary Rozenman, PhD, SVP, Corp. Dev. & Strategy
  • Contact Info
  • Aimmune Therapeutics Inc.
    Phone: (650) 614-5220
    8000 Marina Blvd.
    Ste. 300
    Brisbane, CA 94005
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register